• Skip to primary navigation
  • Skip to main content
  • Skip to footer
  • About
  • Our Products
    • Restoret
  • Team
EyeBio

EyeBio

  • Business Development
  • News
  • Contact

Back to Team

Paul Stephens, Ph.D.

Senior Vice President, Chemistry, Manufacturing, and Controls

LinkedIn

Paul joined EyeBio as Senior Vice President of Chemistry, Manufacturing, and Controls (CMC). He is responsible for early candidate selection and development of EyeBio’s large-molecule portfolio.

Paul has more than 35 years of experience in the biotechnology industry. With over 50 peer-reviewed publications, he is an expert in antibody drug development and expression. Previously, Paul was Senior Director and Head of Antibody Biology at UCB, where he was responsible for the company’s early antibody pipeline and oversaw the transition of UCB’s novel biological entities (NBEs) from the research stage into development. While at UCB, Paul was actively involved in the development of both Evenity® (romosozumab) and Bimzelx® (bimekizumab).

Paul received B.Sc. in Biochemistry from Southampton University, and he completed his Ph.D. at Sheffield University.

Footer

Contact Us

Please fill out the brief form below with any questions or inquiries, and a member of our team will connect with you soon.

Business Development

EyeBio is bringing disruptive innovation to the field of ophthalmology. We actively seek to expand our pipeline of promising investigational therapies, and we welcome inquiries regarding in-licensing and acquisition of assets into our portfolio.

To learn more, please contact Sarah Milsom, Chief Operating Officer of EyeBio, at s.milsom@nulleyebiotech.com.

Privacy Policy
Terms of Use
Cookie Policy
Accessibility Statement

EyeBio

LinkedIn

Copyright © 2022 EyeBio

logo
  • About
  • Our Products
    • Restoret
  • Team
  • Business Development
  • News
  • Contact